Compare ALEMBIC PHARMA with Glenmark Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC PHARMA vs GLENMARK PHARMA - Comparison Results

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC PHARMA GLENMARK PHARMA ALEMBIC PHARMA/
GLENMARK PHARMA
 
P/E (TTM) x 17.4 17.7 98.3% View Chart
P/BV x 6.9 2.9 237.9% View Chart
Dividend Yield % 0.5 0.3 159.2%  

Financials

 ALEMBIC PHARMA   GLENMARK PHARMA
EQUITY SHARE DATA
    ALEMBIC PHARMA
Mar-19
GLENMARK PHARMA
Mar-19
ALEMBIC PHARMA/
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs664712 93.3%   
Low Rs412484 85.3%   
Sales per share (Unadj.) Rs208.7349.6 59.7%  
Earnings per share (Unadj.) Rs31.032.8 94.6%  
Cash flow per share (Unadj.) Rs37.144.3 83.7%  
Dividends per share (Unadj.) Rs5.502.00 275.0%  
Dividend yield (eoy) %1.00.3 305.4%  
Book value per share (Unadj.) Rs144.2198.6 72.6%  
Shares outstanding (eoy) m188.52282.17 66.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.61.7 150.9%   
Avg P/E ratio x17.418.2 95.2%  
P/CF ratio (eoy) x14.513.5 107.6%  
Price / Book Value ratio x3.73.0 124.0%  
Dividend payout %17.76.1 290.8%   
Avg Mkt Cap Rs m101,461168,625 60.2%   
No. of employees `000NA12.0 0.0%   
Total wages/salary Rs m7,46720,561 36.3%   
Avg. sales/employee Rs ThNM8,196.0-  
Avg. wages/employee Rs ThNM1,708.1-  
Avg. net profit/employee Rs ThNM768.5-  
INCOME DATA
Net Sales Rs m39,34798,655 39.9%  
Other income Rs m942,081 4.5%   
Total revenues Rs m39,441100,736 39.2%   
Gross profit Rs m8,73615,858 55.1%  
Depreciation Rs m1,1523,259 35.4%   
Interest Rs m1843,346 5.5%   
Profit before tax Rs m7,49311,335 66.1%   
Minority Interest Rs m110-   
Prior Period Items Rs m-930-   
Extraordinary Inc (Exp) Rs m01,672 0.0%   
Tax Rs m1,5683,756 41.7%   
Profit after tax Rs m5,8449,250 63.2%  
Gross profit margin %22.216.1 138.1%  
Effective tax rate %20.933.1 63.1%   
Net profit margin %14.99.4 158.4%  
BALANCE SHEET DATA
Current assets Rs m19,57766,968 29.2%   
Current liabilities Rs m14,89640,211 37.0%   
Net working cap to sales %11.927.1 43.9%  
Current ratio x1.31.7 78.9%  
Inventory Days Days9083 107.7%  
Debtors Days Days4581 55.9%  
Net fixed assets Rs m27,09733,322 81.3%   
Share capital Rs m377282 133.6%   
"Free" reserves Rs m26,81155,770 48.1%   
Net worth Rs m27,18856,052 48.5%   
Long term debt Rs m4,99335,738 14.0%   
Total assets Rs m47,778132,888 36.0%  
Interest coverage x41.74.4 950.5%   
Debt to equity ratio x0.20.6 28.8%  
Sales to assets ratio x0.80.7 110.9%   
Return on assets %12.69.5 133.1%  
Return on equity %21.516.5 130.2%  
Return on capital %23.617.8 132.5%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m19,45362,998 30.9%   
Fx outflow Rs m6,06522,859 26.5%   
Net fx Rs m13,38840,140 33.4%   
CASH FLOW
From Operations Rs m8,12013,242 61.3%  
From Investments Rs m-7,556-6,990 108.1%  
From Financial Activity Rs m590-7,387 -8.0%  
Net Cashflow Rs m1,153-2,971 -38.8%  

Share Holding

Indian Promoters % 74.1 48.3 153.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 2.9 6.9 42.0%  
FIIs % 9.1 34.4 26.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 13.9 10.5 132.4%  
Shareholders   49,328 56,727 87.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC PHARMA With:   AJANTA PHARMA  FDC  SUN PHARMA  FRESENIUS KABI ONCO.  TTK HEALTHCARE  

Compare ALEMBIC PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

6 Reasons Why Sensex Plunged 883 Points Today(Closing)

Indian share markets nosedived and registered sharp losses in today's volatile session following a strong second wave of Covid-19 in the country.

Related Views on News

ALEMBIC PHARMA Announces Quarterly Results (3QFY21); Net Profit Up 13.8% (Quarterly Result Update)

Jan 19, 2021 | Updated on Jan 19, 2021

For the quarter ended December 2020, ALEMBIC PHARMA has posted a net profit of Rs 3 bn (up 13.8% YoY). Sales on the other hand came in at Rs 13 bn (up 8.7% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

ALEMBIC PHARMA Announces Quarterly Results (2QFY21); Net Profit Up 30.0% (Quarterly Result Update)

Oct 23, 2020 | Updated on Oct 23, 2020

For the quarter ended September 2020, ALEMBIC PHARMA has posted a net profit of Rs 3 bn (up 30.0% YoY). Sales on the other hand came in at Rs 15 bn (up 17.4% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

GLENMARK PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 132.5% (Quarterly Result Update)

Sep 1, 2020 | Updated on Sep 1, 2020

For the quarter ended June 2020, GLENMARK PHARMA has posted a net profit of Rs 3 bn (up 132.5% YoY). Sales on the other hand came in at Rs 23 bn (up 0.9% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

GLENMARK PHARMA Announces Quarterly Results (3QFY20); Net Profit Up 64.0% (Quarterly Result Update)

Feb 19, 2020 | Updated on Feb 19, 2020

For the quarter ended December 2019, GLENMARK PHARMA has posted a net profit of Rs 2 bn (up 64.0% YoY). Sales on the other hand came in at Rs 27 bn (up 7.1% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

ALEMBIC PHARMA Announces Quarterly Results (3QFY20); Net Profit Up 33.3% (Quarterly Result Update)

Jan 23, 2020 | Updated on Jan 23, 2020

For the quarter ended December 2019, ALEMBIC PHARMA has posted a net profit of Rs 2 bn (up 33.3% YoY). Sales on the other hand came in at Rs 12 bn (up 18.8% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

More Views on News

Most Popular

India: Recovery Stalled by Vaccine Games?(The Honest Truth)

Apr 13, 2021

Ajit Dayal on how India's vaccine strategy will impact the markets.

4 Stocks to Make Your Portfolio Immune to the Second Covid Wave(Profit Hunter)

Apr 6, 2021

Rather than predicting the market, successful investing is more about preparing well and placing your bets accordingly.

A Stock with 700% Return Potential Comes with Additional Payoffs(Profit Hunter)

Apr 15, 2021

Narayana Murthy was one of the first unicorn founders to get the backing of this entity...

Why Did the Market Crash on Monday?(Fast Profits Daily)

Apr 13, 2021

In this video, I'll you what I think is the real reason behind yesterday's market crash.

A Unique Sector for Short-Term Profits(Fast Profits Daily)

Apr 12, 2021

This ignored sector could deliver big short-term profits.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC PHARMA SHARE PRICE


Apr 19, 2021 (Close)

TRACK ALEMBIC PHARMA

  • Track your investment in ALEMBIC PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALEMBIC PHARMA

ALEMBIC PHARMA 8-QTR ANALYSIS

COMPARE ALEMBIC PHARMA WITH

MARKET STATS